Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Macular dystrophy; and very common findings: Hypoautofluorescent retinal lesion and Reduced visual acuity. 7 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 5 | Hypoautofluorescent retinal lesion, Macular atrophy, Macular dystrophy |
SAMD7 function has not been fully characterized.
Macular dystrophy with or without cone dysfunction is associated with mutations in the SAMD7 gene on chromosome 3.
Genetic testing for SAMD7 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for macular dystrophy with or without cone dysfunction has been reported in the published literature.
Phenotype severity distribution: 1 always present feature, 2 very common features, 1 common feature.
No clinical trials have been registered for macular dystrophy with or without cone dysfunction.
200 publications have been identified in PubMed for macular dystrophy with or without cone dysfunction. Kisho has analyzed 113 by research type. Research spans Review / Meta-Analysis (41%), Basic Science / Preclinical (25%), and Epidemiology / Natural History (13%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 46 | 41% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 11:53 AM UTC
Online Mendelian Inheritance in Man
2 |
Macular atrophy, Retinal pigment epithelial atrophy |
Laboratory research |
28 |
25% |
Disease patterns and progression | 15 | 13% |
Patient case studies | 8 | 7% |
Other research | 6 | 5% |
New treatment approaches | 5 | 4% |
Testing and diagnosis research | 4 | 4% |
Clinical study results | 1 | 1% |
Miura M (2026). [PMID: 42151388](https://pubmed.ncbi.nlm.nih.gov/42151388/). *Sci Rep*. [Other]
Laich Y (2026). [PMID: 42217979](https://pubmed.ncbi.nlm.nih.gov/42217979/). *Handb Clin Neurol*. [Review / Meta-Analysis]
Amaxilati E (2026). [PMID: 41744818](https://pubmed.ncbi.nlm.nih.gov/41744818/). *Cells*. [Review / Meta-Analysis]
Gardner A (2026). [PMID: 41655020](https://pubmed.ncbi.nlm.nih.gov/41655020/). *Mol Ther*. [Gene Therapy / Novel Therapeutics]
Alibrandi S (2026). [PMID: 42123608](https://pubmed.ncbi.nlm.nih.gov/42123608/). *Int J Mol Sci*. [Other]
Shen W (2025). [PMID: 40578594](https://pubmed.ncbi.nlm.nih.gov/40578594/). *Exp Eye Res*. [Basic Science / Preclinical]
Diaz A (2025). [PMID: 40736823](https://pubmed.ncbi.nlm.nih.gov/40736823/). *Adv Exp Med Biol*. [Review / Meta-Analysis]
Kobayashi K (2025). [PMID: 41107067](https://pubmed.ncbi.nlm.nih.gov/41107067/). *J Neurosci*. [Basic Science / Preclinical]
Al-Khuzaei S (2025). [PMID: 41465146](https://pubmed.ncbi.nlm.nih.gov/41465146/). *Genes (Basel)*. [Basic Science / Preclinical]
Bhandari SK (2025). [PMID: 41516080](https://pubmed.ncbi.nlm.nih.gov/41516080/). *Int J Mol Sci*. [Review / Meta-Analysis]